Amanda G Rodrigues, Allan R K Sales, Diego Faria, Silvia M R Fonseca, Marina M K Bond, Camila P Jordao, Francis R de Souza, Cristina S Bittar, Marilia H H Dos Santos, Adriana O Sarmento, Marcelo V Negrao, Ludhmila A Hajjar, Carlos E Negrão, Roberto Kalil Filho
Cardiotoxicity is the most worrying cardiovascular alteration in patients treated with chemotherapy. To improve the understanding regarding the cardiotoxicity, we studied whether: 1) patients with cardiac dysfunction related to anthracycline-based chemotherapy have augmented sympathetic nerve activity and decreased exercise capacity and 2) these responses are similar to those observed in patients with heart failure caused by other etiologies. Sixteen patients with heart failure with reduced ejection fraction related to anthracycline-based chemotherapy with or without chest radiation (HFrEFCA), 10 patients with heart failure with reduced ejection not related to cancer therapy (HFrEF), and 16 age-and body mass index (BMI)-matched healthy controls were studied...
September 8, 2023: American Journal of Physiology. Heart and Circulatory Physiology